MedTrace Logo

The Effect of Exogenous Glucagon-like Peptide 2 on Cholecystokinin-induced Gallbladder Emptying

NCT04651868 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-12-09

No results posted yet for this study

Summary

The study is a randomized, double-blinded, placebo-controlled, cross-over study, which will investigate the acute effects of the gut-derived hormone glucagon-like peptide 2 (GLP-2) on cholecystokinin (CCK)-induced gallbladder emptying. Furthermore, the investigators will investigate different hormonal responses and appetite during the study days.

The investigators hypothesize that GLP-2 will overrule the potent gallbladder relaxing effect of CCK.

We will include 15 healthy male participants, and each of the participants will participate in four study days. GLP-2 and CCK will be given intravenously, and will be placebo-controlled. Gallbladder volume will be determined by frequent ultrasonography scans. Appetite will be assessed by Visual Analog Scales through out the study day and an ad libitum meal at the end of the study day. Blood samples will be drawn at regular intervals to asses different hormonal responses.

Conditions

  • Gallbladder

Interventions

OTHER

GLP-2

A 210 mins intravenous infusion with GLP-2 (10 pmol × kg\^-1 × min\^-1)

OTHER

Placebo

A 210 mins intravenous infusion with isotonic NaCl

OTHER

CCK

A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg\^-1 × min\^-1)

OTHER

Placebo

A 180 mins intravenous infusion with isotonic NaCl

Sponsors & Collaborators

  • The Novo Nordisk Foundation Center for Basic Metabolic Research

    collaborator OTHER

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Nina L Hansen, MD · Center for Clinical Metabolic Research, Genofte University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-10
Primary Completion
2021-04-27
Completion
2021-04-27

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04651868 on ClinicalTrials.gov